Fan L, Strasser-Weippl K, Li JJ, Louis J St, Finkelstein DM, Yu KD et al. Breast cancer in China. Lancet Oncol 2014; 15: e279–e289.
Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med 2014; 2: 61.
Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A. Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev 2008; 60: 173–183.
Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265–277.
Geginat J, Nizzoli G, Paroni M, Maglie S, Larghi P, Pascolo S et al. Immunity to pathogens taught by specialized human dendritic cell subsets. Front Immunol 2015; 6: 527.
Kajihara M, Takakura K, Ohkusa T, Koido S. The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies. Immunotherapy 2015; 7: 1111–1122.
Anderson KS. Tumor vaccines for breast cancer. Cancer Invest 2009; 27: 361–368.
Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother 2014; 10: 52–63.
Koido S, Hara E, Homma S, Fujise K, Gong J, Tajiri H. Dendritic/tumor fusion cell-based vaccination against cancer. Arch Immunol Ther Exp (Warsz) 2007; 55: 281–287.
Zhang Y, Ma B, Zhou Y, Zhang M, Qiu X, Sui Y et al. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat 2007; 105: 277–286.
Koido S, Tanaka Y, Tajiri H, Gong J. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine 2007; 25: 2610–2619.
Zhou J, Ma P, Li J, Song W. Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells pulsed with recombinant adeno-associated virus carrying alpha-fetoprotein gene or cancer cell lysate. Mol Med Rep 2015; 11: 3174–3180.
Zheng L, Weilun Z, Minghong J, Yaxi Z, Shilian L, Yanxin L et al. Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice. BMC Cancer 2012; 12: 153.
He ZH, Lei Z, Zhen Y, Gong W, Huang B, Yuan Y et al. Adeno-associated virus-mediated expression of recombinant CBD-HepII polypeptide of human fibronectin inhibits metastasis of breast cancer. Breast Cancer Res Treat 2014; 143: 33–45.
Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997; 57: 759–764.
Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res 2014; 16: 204.
Ernst B, Anderson KS. Immunotherapy for the treatment of breast cancer. Curr Oncol Rep 2015; 17: 5.
Goel G, Sun W. Cancer immunotherapy in clinical practice – the past, present, and future. Chin J Cancer 2014; 33: 445–457.
Zhang X, Xu J, Lawler J, Terwilliger E, Parangi S. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res 2007; 13: 3968–3976.
Mahadevan M, Liu Y, You C, Luo R, You H, Mehta JL et al. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol Immunother 2007; 56: 1615–1624.
Sallusto F. DCs: a dual bridge to protective immunity. Nat Immunol 2013; 14: 890–891.
Simon T, Tanguy-Royer S, Royer PJ, Boisgerault N, Frikeche J, Fonteneau JF et al. Human dendritic cells sequentially matured with CD4(+) T cells as a secondary signal favor CTL and long-term T memory cell responses. Biol Res 2012; 45: 33–43.
Batchu RB, Gruzdyn OV, Moreno-Bost AM, Szmania S, Jayandharan G, Srivastava A et al. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine 2014; 32: 938–943.
Wang XL, Ma B, Jia J, Yuan YH, Yan Y, Di LJ et al. [Dendritic cells infected by recombinant adeno-associated virus with CEA gene to induce antigen-specific CTL response to CD44(+)CD24(-/low) cells from MCF-7 breast cancer cell line]. Beijing Da Xue Xue Bao 2011; 43: 173–178.
Chau J, Moza D, Hossain N, Lee JK, Bienenstock J, Karimi K. Increased production of IFN-gamma by natural killer cells triggered with bone marrow-derived dendritic cells cultured in the presence of retinoic acid. Eur J Pharmacol 2013; 715: 321–327.
Steel JC, Di Pasquale G, Ramlogan CA, Patel V, Chiorini JA, Morris. JC. Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer. Mol Ther 2013; 21: 680–687.
Yiang GT, Chou PL, Tsai HF, Chen LA, Chang WJ, Yu YL et al. Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice. Int J Mol Med 2012; 29: 809–814.
Luo J, Luo Y, Sun J, Zhou Y, Zhang Y, Yang X. Adeno-associated virus-mediated cancer gene therapy: current status. Cancer Lett 2015; 356: 347–356.
Montagna D, Turin I, Schiavo R, Montini E, Zaffaroni N, Villa R et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy 2012; 14: 80–90.
Di L, Zhu Y, Jia J, Yu J, Song G, Zhang J et al. Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients. Clin Transl Oncol 2012; 14: 675–681.
Milani A, Sangiolo D, Aglietta M, Valabrega G. Recent advances in the development of breast cancer vaccines. Breast Cancer (Dove Med Press) 2014; 6: 159–168.
Glas J, Seiderer J, Bues S, Stallhofer J, Fries C, Olszak T et al. IRGM variants and susceptibility to inflammatory bowel disease in the German population. PLoS One 2013; 8: e54338.